Company Overview
Snapshot
Founded in October 2012, MobileODT operates with 1–10 employees. The company has raised a total of $22.48 million across 7 funding rounds from 6 investors. In January 2022, MobileODT announced the release of a next-generation AI algorithm for cervical cancer screening, signaling continued innovation in its core technology.
Business overview
MobileODT develops optical diagnostic devices and software services for early cancer detection and various medical purposes. The company leverages advanced optical technology to transform smartphones into mobile point-of-care tools, enabling cancer detection and biomedical image capture for diagnostics. MobileODT also provides intuitive app-based programs to operate its devices, connecting them to a cloud-based software platform for remote consultation and integration with electronic health records. Its product portfolio includes the FDA-cleared EVA COLPO portable colposcope, the EVA SANE forensic documentation system, and the.
Strategic signal
In January 2022, MobileODT released a next-generation AI algorithm for cervical cancer screening. This development indicates the company's continuous commitment to advancing its core technology and improving diagnostic accuracy, which is a strong signal to investors about its potential for market leadership and impact in the femtech and digital medical diagnostics space.
Log in to access full profile ›Company Intelligence Q&A
- What is MobileODT's primary focus?
- MobileODT primarily focuses on developing AI-based cervical cancer screening solutions, utilizing optical diagnostic devices and software services for early detection and other medical purposes.
- When was MobileODT founded?
- MobileODT was founded in October 2012.
- What significant product update did MobileODT announce in January 2022?
- In January 2022, MobileODT announced the release of a next-generation AI algorithm for cervical cancer screening, enhancing its diagnostic capabilities.
- What was a key grant received by MobileODT in January 2021?
- In January 2021, MobileODT was awarded a prestigious grant from the National Cancer Institute (NCI) to further its work in femtech and cervical cancer screening.
- What is the EVA COLPO?
- The EVA COLPO is an FDA-cleared, internet-connected portable colposcope developed by MobileODT, designed to be as user-friendly as a mobile phone for various clinical needs.